By Lisa Kerner
Charlotte, N.C., June 26 - Adnexus Therapeutics, Inc. said it closed a $27 million round of series B financing.
Proceeds will be used to fund development of its lead product candidate, Angiocept (CT-322), through phase 2 clinical development and to advance its pipeline of preclinical product candidates in multiple disease areas.
The financing was led by Venrock Associates, joined by founding investors Atlas Venture, Flagship Ventures and Polaris Venture Partners.
Anders Hove, of Venrock Associates, will join the Adnexus board of directors.
Adnexus is a pharmaceutical company located in Waltham, Mass.
| Issuer: | Adnexus Therapeutics, Inc.
|
| Issue: | Series B financing
|
| Amount: | $27 million
|
| Investors: | Venrock Associates (lead), Atlas Venture, Flagship Ventures, Polaris Venture Partners
|
| Announcement date: | June 26
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
